Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention.
about
Heparin versus placebo for acute coronary syndromesBivalirudin: an anticoagulant option for percutaneous coronary interventionEnoxaparin in acute coronary syndromesLeveraging physiological data from literature into a pharmacokinetic model to support informative clinical study design in pregnant women.Low-molecular-weight heparins in the cardiac catheterization laboratoryDevelopment of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation.Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists.Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety.Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis.Pharmacological antithrombotic adjuncts to percutaneous coronary intervention.Bleeding complications in patients with acute coronary syndromes: are they important and how can we prevent them?Low molecular weight heparin-induced pharmacological modulation of burn wound healing.Anticoagulant therapy in acute coronary syndromes.Successful thrombolysis following enoxaparin therapy in two pediatric patients with congenital heart disease presenting with intracardiac and cerebral thrombosis.Activity of a synthetic hexadecasaccharide (SanOrg123781A) in a pig model of arterial thrombosis.Factor Xa inhibitors in acute coronary syndromes: moving from mythology to reality.First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.
P2860
Q24243000-A6E9C51F-62B6-4CA9-94E4-5D0A1E5BBA34Q28168650-CBCA71D4-DA03-4515-A464-D12B3D41C27EQ28301431-E137E564-81E9-4995-B3C5-542562E510D9Q34127900-3D88C0DD-D1C4-41BB-A110-2CAABA9FB1B6Q35733959-7AF6D411-74C0-4E55-9354-91234FC89CBDQ35827649-97D6C8C7-88C6-480E-A611-EF254FD6D4FAQ36062161-71AD60CD-5586-45FB-ACF8-4435EE51EDC4Q36128828-BCC2BDCA-072D-42CB-9DAF-ACCDC7A5045DQ36131116-E64E1D07-CF27-4BD8-B241-06977901F847Q36787291-D669EE8F-A0FF-42E3-8665-8C2DBFCE6729Q38012078-A4DDF167-FF3B-4FD1-B92E-58ED40C477E6Q38638686-A59D7804-6544-4FFB-930F-730113C23D5AQ40218722-C96B1EBC-5E7F-498F-A4E8-4A2A4974DFA7Q42085080-412BAF65-509B-4D14-93BC-0A1C3FCB0EF6Q44893876-84CFE452-CB35-453A-BE35-0D59DA464522Q45302037-5D66A530-7832-42FC-9231-0F56BD75405CQ45302042-3E294261-F209-445A-BAF3-4E7CDF5DB691Q53292171-58737CB4-FA86-4665-A939-D359F5DA3774
P2860
Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Use of low-molecular-weight he ...... taneous coronary intervention.
@en
type
label
Use of low-molecular-weight he ...... taneous coronary intervention.
@en
prefLabel
Use of low-molecular-weight he ...... taneous coronary intervention.
@en
P356
P1476
Use of low-molecular-weight he ...... taneous coronary intervention.
@en
P2093
Graham C Wong
Robert P Giugliano
P304
P356
10.1001/JAMA.289.3.331
P407
P577
2003-01-01T00:00:00Z